clinical trials

For the first time, there's scientific evidence that a smaller, lesser known component of cannabis – cannabinol – delivers better quality and longer sleep. It proved to be comparable to existing sleep aids, without the undesirable side effects.

Game-changing GLP-1 agonist drugs are a step closer to being available in oral pill form, with AstraZeneca revealing "encouraging data" from the Phase I safety and tolerability trial of its once-daily obesity and diabetes drug AZD5004.

While growing evidence suggests that there’s a link between blood iron levels and the development of Alzheimer’s disease, new research investigating the effects of an available iron-reducing drug has raised concerns about its use as a treatment for the condition.

A new review has highlighted how skin tone can affect the safety and effectiveness of some medications and why the current way we run clinical drug trials needs to change to include more historically underrepresented populations.